ROCHESTER, N.Y., YORK, England and BETHESDA, Md., April 1 /PRNewswire-Asia/ -- ACM Global Central Laboratory, the laboratory that continually defines the client-service standard with its inherently flexible approach, and Chindex International, Inc. (Nasdaq: CHDX), today announced a partnership to provide central lab services in China at United Family Hospitals, Beijing (UFH). UFH is a CAP-certified facility owned by Chindex International, Inc.
ACM Global Central Laboratory conducted a harmonization program in China, and chose to work with Chindex in order to ensure the same degree of global standards that clients enjoy from the Americas, Europe, India and Australasia. Offering on-the-ground central lab capabilities in China is a significant milestone in the organization's history.
"Given the challenges of exporting whole blood from Mainland China coupled with the demand for conducting trials in China, we recognized the importance of establishing services locally," said Elena Logan, Vice President, ACM Global Central Laboratory. "We also refuse to compromise on quality and working with Chindex helps us maintain our rigorous service standards in an exciting developing market. I'm honored to be able to work with the UFH team led by US trained pathologist, Dr. Sun Fei, who will oversee the clinical trial efforts at UFH."
"As the only Western-founded hospital lab in Beijing, and the only JCI accredited hospital in China with CAP accreditation, UFH is well-poised to provide unparalleled central lab services. Working with a global leader like ACM acknowledges our unique competitive position as well as our dedication to high standards of care. We also look forward to providing additional diagnostic testing to the local community through this partnership," said Roberta Lipson, CEO of Chindex.
|SOURCE Chindex International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved